Quantitative MRI biomarker for treatment response assessment of multiple myeloma: robustness evaluation using independent test set of prospective cases

2019 ◽  
Author(s):  
Chuan Zhou ◽  
Qian Dong ◽  
Heang-Ping Chan ◽  
Erica L. Campagnaro ◽  
Jun Wei ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Treatment Response ◽  
Response Assessment ◽  
Quantitative Mri ◽  
Test Set ◽  
Independent Test ◽  
Treatment Response Assessment

Multiple Myeloma Treatment Response Assessment with Whole-Body Dynamic Contrast-enhanced MR Imaging

Radiology ◽  
2010 ◽  
Vol 254 (2) ◽  
pp. 521-531 ◽  
Author(s):  
Chieh Lin ◽  
Alain Luciani ◽  
Karim Belhadj ◽  
Jean-François Deux ◽  
Frédérique Kuhnowski ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Mr Imaging ◽  
Treatment Response ◽  
Response Assessment ◽  
Whole Body ◽  
Dynamic Contrast Enhanced ◽  
Contrast Enhanced ◽  
Treatment Response Assessment ◽  
Body Dynamic

Multiple Myeloma: Role of Imaging in Diagnosis, Staging, and Treatment Response Assessment

2020 ◽  
Author(s):  
Sameh Nassar ◽  
Ahmed Taher ◽  
Rosario Spear ◽  
Felicia Wang ◽  
John E. Madewell ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Treatment Response ◽  
Response Assessment ◽  
Treatment Response Assessment

scholarly journals Deep Learning-Based Computer-Aided Detection System for Automated Treatment Response Assessment of Brain Metastases on 3D MRI

2021 ◽  
Vol 11 ◽  
Author(s):  
Jungheum Cho ◽  
Young Jae Kim ◽  
Leonard Sunwoo ◽  
Gi Pyo Lee ◽  
Toan Quang Nguyen ◽  
...  
Keyword(s):  
Deep Learning ◽  
Brain Metastases ◽  
Treatment Response ◽  
Response Assessment ◽  
Computer Aided Detection ◽  
Mr Images ◽  
Test Set ◽  
One Dimensional ◽  
Computer Aided ◽  
Treatment Response Assessment

BackgroundAlthough accurate treatment response assessment for brain metastases (BMs) is crucial, it is highly labor intensive. This retrospective study aimed to develop a computer-aided detection (CAD) system for automated BM detection and treatment response evaluation using deep learning.MethodsWe included 214 consecutive MRI examinations of 147 patients with BM obtained between January 2015 and August 2016. These were divided into the training (174 MR images from 127 patients) and test datasets according to temporal separation (temporal test set #1; 40 MR images from 20 patients). For external validation, 24 patients with BM and 11 patients without BM from other institutions were included (geographic test set). In addition, we included 12 MRIs from BM patients obtained between August 2017 and March 2020 (temporal test set #2). Detection sensitivity, dice similarity coefficient (DSC) for segmentation, and agreements in one-dimensional and volumetric Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM) criteria between CAD and radiologists were assessed.ResultsIn the temporal test set #1, the sensitivity was 75.1% (95% confidence interval [CI]: 69.6%, 79.9%), mean DSC was 0.69 ± 0.22, and false-positive (FP) rate per scan was 0.8 for BM ≥ 5 mm. Agreements in the RANO-BM criteria were moderate (κ, 0.52) and substantial (κ, 0.68) for one-dimensional and volumetric, respectively. In the geographic test set, sensitivity was 87.7% (95% CI: 77.2%, 94.5%), mean DSC was 0.68 ± 0.20, and FP rate per scan was 1.9 for BM ≥ 5 mm. In the temporal test set #2, sensitivity was 94.7% (95% CI: 74.0%, 99.9%), mean DSC was 0.82 ± 0.20, and FP per scan was 0.5 (6/12) for BM ≥ 5 mm.ConclusionsOur CAD showed potential for automated treatment response assessment of BM ≥ 5 mm.

scholarly journals Comparison of [18F]FDG PET/CT and MRI for Treatment Response Assessment in Multiple Myeloma: A Meta-Analysis

Diagnostics ◽  
2021 ◽  
Vol 11 (4) ◽  
pp. 706
Author(s):  
Kota Yokoyama ◽  
Junichi Tsuchiya ◽  
Ukihide Tateishi
Keyword(s):  
Multiple Myeloma ◽  
Treatment Response ◽  
Fdg Pet ◽  
Meta Analysis ◽  
Response Assessment ◽  
Pet Ct ◽  
Treatment Response Assessment ◽  
18F Fdg ◽  
Fdg Pet Ct ◽  
Ct And Mri

The present study was designed to assess the additional value of 2-deoxy-2[18F]fluoro-D-glucose ([18F]FDG) positron emission tomography/computed tomography (PET/CT) to magnetic resonance imaging (MRI) in the treatment response assessment of multiple myeloma (MM). We performed a meta-analysis of all available studies to compare the detectability of treatment response of [18F]FDG PET/CT and MRI in treated MM. We defined detecting a good therapeutic effect as positive, and residual disease as negative. We determined the sensitivities and specificities across studies, calculated the positive and negative likelihood ratios (LR), and made summary receiver operating characteristic curves (SROC) using hierarchical regression models. The pooled analysis included six studies that comprised 278 patients. The respective performance characteristics (95% confidence interval (CI)) of [18F]FDG PET/CT and MRI were as follows: sensitivity of 80% (56% to 94%) and 25% (19% to 31%); specificity of 58% (44% to 71%) and 83% (71% to 91%); diagnostic odds ratio (DOR) of 6.0 (3.0–12.0) and 1.7 (0.7–2.7); positive LR of 1.8 (1.3–2.4) and 1.4 (0.7–2.7); and negative LR of 0.33 (0.21–0.53) and 0.81 (0.62–1.1). In the respective SROC curves, the area under the curve was 0.77 (SE, 0.038) and 0.59 (SE, 0.079) and the Q* index was 0.71 and 0.57. Compared with MRI, [18F]FDG PET/CT had higher sensitivity and better DOR and SROC curves. Compared with MRI, [18F]FDG PET/CT had greater ability to detect the treatment assessment of MM.

Multi‐parametric MRI (mpMRI) for treatment response assessment of radiation therapy

2021 ◽  
Author(s):  
Chunhao Wang ◽  
Kyle R. Padgett ◽  
Min‐Ying Su ◽  
Eric A. Mellon ◽  
Danilo Maziero ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Treatment Response ◽  
Response Assessment ◽  
Treatment Response Assessment
Sign in / Sign up

Export Citation Format

Share Document